Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | L617V |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 L617V (also referred to as V618V from the FGFR2IIIb isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L617V has been shown to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880), and demonstrates increased Fgfr2 kinase activity compared to wild-type in an in vitro assay (PMID: 28166054), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 L617V |
Transcript | NM_000141.5 |
gDNA | chr10:g.121496546A>C |
cDNA | c.1849T>G |
Protein | p.L617V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000141.5 | chr10:g.121496546A>C | c.1849T>G | p.L617V | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121496546A>C | c.1849T>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_017015925 | chr10:g.121485447G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
NM_001144916.1 | chr10:g.121485396G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_006717712 | chr10:g.121485456G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_017015925.2 | chr10:g.121485447G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_017015925.3 | chr10:g.121485447G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_024447891.2 | chr10:g.121485456G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
NM_001144916.2 | chr10:g.121485396G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
NM_001144916 | chr10:g.121485396G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121496546A>C | c.1849T>G | p.L617V | RefSeq | GRCh38/hg38 |
XM_024447891.1 | chr10:g.121485456G>C | c.1849C>G | p.L617V | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 L617V | Advanced Solid Tumor | predicted - sensitive | Lirafugratinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lirafugratinib treatment inhibited Fgfr2 phosphorylation in cultured cells expressing FGFR2 L617V (PMID: 37270847). | 37270847 |